||
FDA批准JAK抑制剂deuruxolitinib用于治疗成人重度斑秃
斑秃,这一突如其来的头皮疾病,以其局部或全头的无规律脱发,给患者带来了不小的心理与生理挑战。它不仅影响外貌美观,更可能引发患者的自卑、焦虑情绪,甚至影响日常生活和社交活动。
近日,美国食品药品管理局(US Food and Drug Administration,FDA)已批准口服Janus激酶(Janus kinase,JAK)抑制剂deuruxolitinib用于治疗成人重度斑秃。
(254)
(235)
(157)
(151)
(108)
(105)
(101)
(100)
(73)
(71)
https://fx.wanfangdata.com.cn/keytrends/detail?theme_name=%E6%96%91%E7%A7%83
http://www.pubmedplus.cn/P/SearchQuickResult?wd=3fe6968c-0c3f-4b3c-8385-3cda1172ac16
01. | Humans | 105 篇 | 54.974% |
02. | Alopecia Areata | 97 篇 | 50.785% |
03. | Female | 38 篇 | 19.895% |
04. | Male | 33 篇 | 17.277% |
05. | Adult | 30 篇 | 15.707% |
06. | Alopecia | 20 篇 | 10.471% |
07. | Young Adult | 20 篇 | 10.471% |
08. | Middle Aged | 18 篇 | 9.424% |
09. | Hair | 15 篇 | 7.853% |
10. | Child | 14 篇 | 7.330% |
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-8-27 10:15
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社